Non-ionic Contrast Agents for Antisense Oligonucleotide Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering genetic therapies across the blood-brain barrier are inefficient, particularly for widespread neurodegenerative disorders like spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), due to the barrier's restrictive nature, limiting the effectiveness of treatments for these conditions.
Innovation Solution
The use of non-ionic, low-osmolar contrast agents, such as iohexyl, in conjunction with antisense oligonucleotides like morpholinos, to facilitate the delivery of genetic therapies across the blood-brain barrier, enabling targeted delivery to the central nervous system and spinal cord.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional delivery methods are used for genetic therapies, then the blood-brain barrier provides protection, but the barrier prevents widespread delivery to the brain and spinal cord
Solution Approach 1:
The patent uses non-ionic low-osmolar contrast agents as intermediary substances to facilitate the transport of antisense oligonucleotides across the blood-brain barrier. The contrast agent forms a complex with the oligonucleotide, enabling it to traverse the barrier through mechanisms such as transient barrier disruption or enhanced permeability, thereby mediating the transfer from the bloodstream into the CNS without compromising the barrier's protective function against other substances.
2Adaptability or versatility
If multiple injections are used to target widespread neurodegeneration, then coverage of affected regions improves, but the complexity and difficulty of treatment increases
Solution Approach 1:
The patent creates a universal delivery system where a single injection of the contrast agent-antisense oligonucleotide complex can distribute the therapeutic agent throughout multiple affected regions of the CNS simultaneously. The contrast agent's ability to reach various tissues through its pharmacokinetic properties enables one administration to serve multiple target sites, including brain and spinal cord regions, eliminating the need for multiple separate injections.
3Productivity
If viral vectors are used for gene delivery, then transduction efficiency improves, but the requirement for numerous injections to reach widespread regions increases
Solution Approach 1:
The patent employs non-ionic low-osmolar contrast agents that have been pre-engineered with pharmacokinetic properties enabling widespread distribution throughout the CNS. This preliminary preparation of the delivery vehicle allows a single injection to achieve broad distribution before the therapeutic agent is released, eliminating the need for sequential injections required by viral vector approaches and reducing the total treatment time.
Data Source
AI summary
Disclosed are compositions comprising an antisense oligonucleotide and a non-ionic, low-osmolar contrast agent. Also disclosed are methods of delivering an antisense oligonucleotide to a target sire comprising incorporating the antisense oligonucleotide into a composition comprising a non-ionic, low-osmolar contrast agent. Also disclosed are methods of treating a neurodegenerative disease comprising administering one or more of the compositions disclosed herein.